Latest Breaking News On - Surveyor capital - Page 18 : comparemela.com

Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation  Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026 Companies to host conference call today at 8:30 a.m. ET

United kingdomUnited statesRam aiyarSteve collettiVineet agarwalKorro bioShelby walkerTodd chappellVenkat krishnamurthyDavidl lucchinoStephanie engelsAlex silversteinPiper sandlerFidelity management research companyExchange commissionJp morgan securities